Dr. Sachdev is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10510 N 92nd ST
Suite 200
Scottsdale, AZ 85258Phone+1 480-323-1350Fax+1 480-323-1359
Education & Training
University of TennesseeFellowship, Hematology and Medical Oncology, 2004 - 2007
Creighton University School of Medicine/Maricopa Medical Center (Phoenix)Residency, Internal Medicine, 2001 - 2004
Dayanand Medical College Class of 2000
Certifications & Licensure
AZ State Medical License 2010 - 2025
MS State Medical License 2007 - 2012
TN State Medical License 2007 - 2012
AR State Medical License 2008 - 2010
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Clinical Trials
- Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. Start of enrollment: 2008 Oct 01
- Temsirolimus as Second-line Therapy in HCC Start of enrollment: 2010 Feb 01
- A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 461 citationsPhase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.David S. Hong, Yoon-Koo Kang, Mitesh J. Borad, Jasgit C. Sachdev, Samuel Ejadi
British Journal of Cancer. 2020-04-02 - 49 citationsEffect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.Kevin Kalinsky, Fangxin Hong, Carolyn K. McCourt, Jasgit C. Sachdev, Edith P. Mitchell
JAMA Oncology. 2021-02-01 - 5 citationsA phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.Gerald S Falchook, Jasgit Sachdev, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M Mugundu
Investigational New Drugs. 2023-06-01
Press Mentions
Five Prime Therapeutics Presents Monotherapy Data from the Phase 1a/1b Trial of FPA150 in Patients with Advanced Solid Tumors at the 2019 ASCO Annual MeetingJune 1st, 2019
Dr. Jasgit Sachdev on What's on the Horizon for Ovarian CancerNovember 23rd, 2016- Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian CancerOctober 25th, 2016
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
